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Introduction: There are conflicting results in the literature regarding the connection between thrombophilias and
ischaemic stroke. However, most of the clinical studies have not differentiated between various ischaemic stroke
subtypes. Our aim was to investigate whether there is an association between the methylene tetrahydrofolate
reductase (MTHFR) C677T polymorphism and ischaemic stroke due to small vessel disease (SVD) in patients 50
years of age.
Patients and methods: We performed a retrospective search in the database used at our Health Centre. Our study
population consisted of 100 ischaemic stroke patients. 65 patients had MTHFR C677T variants: 21 were homo-
zygous (TT allele), 45 were heterozygous (CT). 35 stroke patients did not carry MTHFR C677T polymorphism
(wild genotype, CC). Stroke subtypes were determined according to the TOAST classification. Pearson's chi-
squared test of independence was used to evaluate differences between subgroups and multivariate logistic
regression was also performed.
Results: More than half of our study population (52.00%) had lacunar strokes. The ratio of SVD in patients 50
years of age with TT homozygous variant was significantly higher compared to heterozygous and wild type
subjects (p ¼ 0.032 and p ¼ 0.03 respectively). Multivariate logistic regression also showed, that apart from
hypertension, only TT homozygosity was a predictive factor for SVD related stroke (p ¼ 0.014, OR 1.619, 95% CI
1.390–18.338).
Conclusion: Our results demonstrate that in a Hungarian population of ischaemic stroke patients 50 years of age,
SVD is the most common stroke subtype. In addition, we found association of SVD stroke with hypertension and
MTHFR 677TT homozygous polymorphism.1. Introduction
Thrombophilias are acquired or inherited hypercoagulable states,
which predispose patients to arterio-venous thrombotic events [1, 2]. It
would seem logical to assume that thrombophilias play a role in the
development of ischaemic stroke. However, for the time being, there is
inconclusive evidence in the literature regarding the connection between
thrombophilias and ischaemic stroke, even in young patients [3]. For
instance, the AHA/ASA guideline for secondary ischaemic stroke or
transient ischaemic attack (TIA) prevention published in 2014, de-
termines the usefulness of searching for thrombophilias as “unknown”
[4]. Consequently, therapeutic recommendations are uncertain in such(P. Klivenyi).
August 2020; Accepted 15 Octo
evier Ltd. This is an open access aconditions. However, it should be kept in mind that the majority of the
studies that investigated the association between ischaemic stroke and
thrombophilias did not differentiate between different stroke subtypes
[5, 6, 7, 8].
Hyperhomocysteinaemia (hHcy) is considered as a risk factor for
cardiovascular diseases [8, 9, 10]. A strong predisposing factor to hHcy is
the polymorphism in the methylene tetrahydrofolate reductase (MTHFR)
gene at position 677. CC genotype is the normal variant, and T is the
pathologic allele [8, 10]. This genetic variant is one of the commonest
forms of inherited thrombophilias [11]. Based on the gnomAD database
(https://gnomad.broadinstitute.org), T allele frequency in all pop-
ulations is 0.3085. There is growing evidence in the literature, that hHcyber 2020
rticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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small vessel disease (SVD) [8, 12, 13].
The aim of our study was to evaluate whether SVD related stroke is
more frequent compared to other subtypes in patients with MTHFR
C677T polymorphism in Hungarian ischaemic stroke patients 50 years
of age. We aimed to investigate a young stroke population to minimize
the chronic atherothrombotic effects of traditional vascular risk factors
(e.g.: hypertension, hyperlipidaemia, diabetes mellitus, etc.), which are
more pronounced in the elderly and would allow for confounding.
2. Patients and methods
2.1. Study population
Our work is a single centre, retrospective, observational study. We did
a retrospective search in the e-Medsolution system used at our Health
Centre to look for patients50 years of age who had a definite ischaemic
stroke and underwent MTHFR genotyping since 2007. We used 50 years
of age as cut-off value since stroke in young adults is usually defined
accordingly in most epidemiological studies [14, 15, 16]. During the
study period, there was no institutional protocol for the indication of
MTHFR genotyping. It was left to the discretion of the treating physician
and was not guided by aetiology. We found 100 patients who fit the in-
clusion criteria. MTHFR C677T polymorphism was found in 65 out of
100 patients (65.00%). 21 had homozygous (TT, 21.00%) and 41 had
heterozygous (CT, 41.00%) variants. 35 patients did not have MTHFR
C677T polymorphism (CC, wild-type subjects, 35.00%). The diagnosis of
ischaemic stroke was set up by an expert in neurology based on clinical
presentation and radiological findings. To determine the stroke subtype,
we applied the Trial of Org 10172 in Acute Stroke Treatment – TOAST
classification [17]. 85 patients (85.00%) had MRI and 15 participants
(15.00%) had CT imaging (with or without angiography). Electrocardi-
ography, carotid ultrasonography and transthoracic echocardiography
were performed in all patients. The diagnosis of lacunar stroke was made
if CT or MRI imaging showed an acute or subacute small vessel territory
ischaemia less than 1.5 cm in diameter which correlated with the
symptoms of the patient. Where the infarct was not clearly visible on
brain imaging, lacunar stroke was diagnosed if there was no evidence of
large-artery atherosclerosis (LAA) or other determined aetiology (e.g.:
dissection), no potential source of cardioembolic stroke (CE), the clinical
symptoms correlated with one of the typical lacunar syndromes and
leukoaraiosis was seen in cases where MRI scans were available [18].
Peripheral blood samples were obtained from all participants to deter-
mine the MTHFR genotype after informed consent was provided. The
study was conducted in accordance with ethical regulations disclosed in
the GINOP (2.3.2-15- 2016-00048) project and approved by Medical
Research Council of Hungarian Ministry of Human Resources
(35403-2/2017/EKU). Informed consent was obtained from all patients
participated in this study.
Hypertension was defined as systolic and/or diastolic blood pressure
140 and 90 mmHg respectively (based on 3 independent measures).
Patients taking anti-hypertensive medications before stroke were
considered hypertensive. Hyperlipidaemia was diagnosed if: a) the pa-
tient had already taken statins or fenofibrate, b) serum cholesterol was
5.20 mmol/l, c) triglyceride level was 1.70 mmol/l or, d) low-density
lipoprotein (LDL) level was 3.00 mmol/l. Diabetes mellitus was diag-
nosed if fasting plasma glucose was 7.00 mmol/l or haemoglobin A1c
level was 6.50%. Patients taking antidiabetic medications (oral or
injective) were also included. History of continuous smoking in the past
or tobacco use at the time of stroke presentation was also addressed.2.2. Laboratory analysis
Peripheral venous blood samples were taken into Vacutainer™ tubes
containing EDTA. Following genomic DNA isolation, MTHFR C677T2
genotyping was performed using real-time PCR with LightCycler probe
system (Roche).
2.3. Statistical analysis
Continuous variables were expressed as mean  SD. Mean of
continuous variable (age) was compared within the MTHFR C677T ge-
notype and TOAST aetiology subgroups with Welch's ANOVA. For cate-
gorical variables Pearson's chi-squared test of independence was applied.
Where sample sizes were small (i.e. equal to, or less than 5) we used
Fisher's exact test. Further analysis was carried out with multivariate
logistic regression. All vascular risk factors (male sex, age, hypertension,
diabetes mellitus, hyperlipidaemia, smoking andMTHFR polymorphism)
were taken into account as candidate predictors of SVD. Backward like-
lihood ratio model selection method was applied. Odds ratio (OR) and
95% confidence intervals (CI) were calculated. Statistical significance
was met when p-value was <0.05. For statistical analysis, IBM SPSS
version 25 statistical software was used.
3. Results
Table 1 summarizes the baseline characteristics of our study popu-
lation. We believe that the groups are well matched, although more
hyperlipidaemic patients were included in the wild-type group. Age
distribution of the study population is shown in Figure 1.
An interesting finding was that more than half of our study population
(52.00%) had SVD related stroke. The second most common aetiology
was cryptogenic stroke (24.00%). Table 2 highlights the distribution of
stroke subtypes in homozygous, heterozygous and wild type patients.
Table 3 demonstrates the risk factor profile of patients with SVD and non-
SVD related stroke.
We found that TT homozygous patients had significantly higher
proportion of strokes due to SVD compared to heterozygous and wild-
type subjects (p ¼ 0.032 and p ¼ 0.03 respectively). Heterozygous pa-
tients did not have more SVD related strokes compared to wild-type
subjects (p ¼ 0.581). Multivariate regression analysis demonstrated the
association of SVD related stroke with hypertension (p ¼ 0.002, OR
1.378, 95% CI 1.624–9.683) and MTHFR TT homozygosity (p ¼ 0.014,
OR 1.619, 95% CI 1.390–18.338).
The frequency of T allele in our study population was 0.4300. When
we examined the allele frequency of T in patients with SVD (0.5000),
compared to patients with non-SVD related strokes (0.3542), the differ-
ence was statistically significant (p ¼ 0.037).
4. Discussion
Polymorphism in the MTHFR gene at positon 677 leads to reduced
enzymatic activity of the MTHFR enzyme [19]. Consequently, there is a
reduced conversion of N [5],N10-methylene tetrahydrofolate to N
[5]-methyl tetrahydrofolate. The latter is required for homocysteine
(Hcy) to be metabolised to L-methionine (Met) by methionine-synthase
[20]. Therefore, it is believed that MTHFR C677T polymorphism is a
strong predisposing factor for hHcy [8, 10]. The conversion of Hcy to Met
also requires folic acid and vitamin B12 as cofactors, explaining why diet
can have an impact on Hcy concentrations. A limitations of our study is
that we did not measure Hcy, folic acid or vitamin B12 levels. It is
important to note however, that serumHcy levels are also influenced by a
variety of comorbidities (e.g.: hyperlipidaemia, renal and hepatic insuf-
ficiency) and medications (metformin, fenofibrate, thiazide diuretics)
[21]. Nonetheless, a mendelian randomisation analysis of
European-descent ischaemic stroke patients found that genetically higher
blood Hcy levels are associated with SVD related stroke, but not with
large artery stroke or cardioembolic stroke [22].
An unexpected finding of our study was the high percentage (52.00%)
of SVD related stroke. Yesilot et al. reported that among European pa-
tients with first-ever ischaemic stroke aged between 42 to 49 years, SVD
Table 1. Demographic data of our study population.
Homozygous
(n ¼ 21)
Heterozygous
(n ¼ 44)
Wild type
(n ¼ 35)
p value
Mean age SD (years) 37.81  9.92 41.68  6.95 42.63  5.85 0.143
Male 14 (66.67%) 22 (50.00%) 25 (71.43%) 0.139
HT 10 (47.62%) 26 (59.09%) 20 (57.14%) 0.692
DM 1 (4.76%) 5 (11.36%) 5 (14.29%) 0.421
HL 8 (38.09%) 15 (34.09%) 24 (68.57%) 0.007
Smoking 10 (47.62%) 20 (45.45%) 20 (57.14%) 0.581
Abbreviations: SD: standard deviation, HT: hypertension, DM: diabetes mellitus, HL: hyperlipidaemia.
Figure 1. Age distribution of our study population.
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termined in 38% in the same cohort, compared to our 24.00%. One
possible explanation for this finding may be the high prevalence of hy-
pertension in our study (56.00%), since hypertension is the mostTable 2. Distribution of stroke subtypes.
TOAST classification Homozygous (n ¼ 21) Heterozyg
LAA 2 (9.52%) 3 (6.82%)
CE 3 (14.29%) 2 (4.55%)
SVD 16 (76.19%) 20 (45.45
O 0 (0.00%) 7 (15.91%
Cr 0 (0.00%) 12 (27.27
Abbreviations: LAA: large-artery atherosclerosis, CE: cardioembolic, SVD: small vesse
Table 3. Risk factor profile of patients with SVD and non-SVD related stroke.
SVD (n ¼ 52)
Mean age SD (years) 42.31  7.94
Male 33 (63.46%)
HT 36 (69.23%)
DM 7 (13.46%)
HL 28 (53.85%)
Smoking 25 (48.08%)
MTHFR C677T homozygosity 16 (30.77%)
MTHFR C677T heterozygosity 20 (38.46%)
MTHFR C677T wild type 16 (30.77%)
Abbreviations: SD: standard deviation, HT: hypertension, DM: diabetes mellitus, HL: h
disease.
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important risk factor for SVD related stroke. Our regression analysis also
demonstrated this association. Putaala et al. published that in a European
population of ischaemic stroke patients under 50 years of age, the
prevalence of hypertension was 35.9% [24]. Therefore, we can conclude
that hypertension was more common in our cohort. The reason behind
this finding however, is unclear. Bias in patient selection due to the
retrospective nature of our study cannot be ruled out. The lower
socio-economic status of the population of South Eastern Hungary
compared to most of the regions that participated in the study by Putaala
et al. could also be a factor in the higher prevalence of hypertension [24,
25].
A novelty of our study is that we have examined the connection be-
tween the MTHFR C677T genotype and stroke subtypes in a young
ischaemic stroke population. Both the chi-squared test and logistic
regression analysis demonstrated association of SVD with MTHFR ho-
mozygous polymorphism. MTHFR C677T heterozygosity was not a risk
factor for SVD.
An important limitation of our study is that genetic testing was left to
the discretion of the treating physician. Consequently, it is possible that
not all patients who fit our inclusion criteria underwent MTHFR C677T
genotyping at our Health Centre since 2007. This, and the retrospective
design of our study could contribute to a potential bias in patient selec-
tion and therefore interpretation of the prevalence of SVD related stroke.
Another shortcoming of our paper is that not all patients had MRI
scans, although a fairly high percent underwent MRI imaging (85.00%).
In patients who were diagnosed as having SVD related stroke, 90.38%ous (n ¼ 44) Wild type (n ¼ 35) Total (n ¼ 100)
2 (5.71%) 7 (7.00%)
1 (2.86%) 6 (6.00%)
49.33%) 16 (45.71%) 52 (52.00%)
) 4 (11.43%) 11 (11.00%)
%) 12 (34.29%) 24 (24.00%)
l disease, O: other determined aetiology, Cr: cryptogenic.
non-SVD (n ¼ 48) p value
40.00  6.82 0.121
28 (58.33%) 0.599
20 (41.67%) 0.006
4 (8.33%) 0.529
19 (39.58%) 0.153
25 (52.08%) 0.689
5 (10.42%) 0.015
24 (50.00%) 0.246
19 (39.58%) 0.356
yperlipidaemia, MTHFR: methylene tetrahydrofolate reductase, SVD: small vessel
A. Annus et al. Heliyon 6 (2020) e05305had MRI scans. We believe that this high percentage reduces the risk of a
potential bias in the determination of SVD, since lacunes and white-
matter hyperintensities can be well visualized on DWI and FLAIR im-
ages. The allele frequency of T was higher in our study population
(0.4300) compared to the allele frequency reported in the general non-
Finnish European population (0.3380, based on gnomAD). This differ-
ence was statistically significant (p¼ 0.006), and implies that the T allele
is more frequent in ischaemic stroke patients. In a meta-analysis, MTHFR
C677T polymorphism was associated with a graded, dose-dependent
increase in ischaemic stroke risk, and the pooled risk estimate in TT
homozygotes was twice compared to CT heterozygotes [26]. Our results
also demonstrate that allele frequency of T is significantly higher among
ischaemic stroke patient due to SVD compared to non-SVD.
A few other studies have investigated the connection between
MTHFR C677T polymorphism and ischaemic stroke subtypes. Choi et al.
demonstrated an association between hHcy, TT homozygous variant and
small artery occlusion [8]. The study population only included Korean
subjects, and the mean age of patients in the stroke arm were higher
compared to our patients (61.4 years). Interestingly, a more significant
connection was found in patients who suffered multiple lacunar strokes
compared to those with single artery occlusion. Due to the small sample
size of our study, we did not perform subgroup analysis to test this
hypothesis.
Another study group found that the MTHFR C677T genotype is
significantly associated with lacunar stroke and white matter hyper-
intensity volume in hypertensive individuals, but not in normotensive
subjects [13]. As expected, the association was more prominent in TT
homozygous patients. This meta-analysis included stroke or TIA patients
in all age groups. As mentioned before, the high percentage of SVD
related stroke in our population might be due to the high prevalence of
hypertension.
Hassan and colleagues were able to demonstrate a connection be-
tween MTHFR C677T variant and ischaemic leukoaraiosis, but not with
isolated lacunar stroke. Mean age of the patients with cerebral small
vessel disease was 67.1 years [27]. Eikelboom et al. did not find a
connection between MTHFR genotype and ischaemic stroke subtypes
[28]. Instead, they demonstrated that hHcy was significantly associated
with large-artery atherosclerosis, and to a lesser extent, with cerebral
small vessel disease.
In conclusion, we believe that our study further supports a role for
MTHFR C677T polymorphism in the development of cerebral small
vessel disease. To our knowledge, we are the first to report this associ-
ation in young ischaemic stroke patient, i.e.  50 years of age. Further-
more, in a subset of Hungarian patients, the frequency of SVD related
stroke was much higher than expected.
The VITATOPS (VITAmins TO Prevent Stroke) trial demonstrated a
modest benefit of vitamin supplementation (daily administration of 2 mg
folic acid, 25 mg vitamin B6, 0.5 mg vitamin B12) in reducing the risk of
stroke, myocardial infarction and vascular death in patients who previ-
ously had symptomatic cerebral small vessel disease (RR 0.80, 95% CI
0.67–0.96) [29]. Therefore, in our opinion, it is reasonable to check the
MTHFR C677T genotype, Hcy, folic acid and vitamin B12 levels in young
ischaemic stroke patients with SVD since vitamin supplementation as
part of secondary stroke prevention therapy might reduce the risk of
stroke recurrence.
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